Abbott Laboratories $ABT Shares Bought by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 1.9% during the 3rd quarter, HoldingsChannel reports. The fund owned 516,943 shares of the healthcare product maker’s stock after acquiring an additional 9,500 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Abbott Laboratories were worth $51,089,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Cornerstone Financial Management LLC purchased a new position in Abbott Laboratories in the fourth quarter valued at about $25,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth about $25,000. Portfolio Resources Advisor Group Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $26,000. Abound Financial LLC acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $26,000. Finally, Manning & Napier Advisors LLC bought a new stake in shares of Abbott Laboratories in the 2nd quarter valued at approximately $31,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays initiated coverage with an Overweight rating and a $120 price target, implying roughly 22% upside from the referenced share price. The bullish initiation adds fresh institutional support and reflects confidence in Abbott’s diversified medical-device and healthcare portfolio. Abbott Laboratories Now Covered by Analysts at Barclays
• Positive Sentiment: Abbott received FDA clearance for updates to its CardioMEMS heart-failure system. The CardioGuide HF App and Dynamic Treatment Plan allow patients to view pulmonary artery pressure data and receive clinician-guided medication adjustments, strengthening Abbott’s connected-care and remote-monitoring strategy. FDA-Approved CardioMEMS App Integration
• Positive Sentiment: The company launched Ensure Max Protein 3-in-1 Muscle Support, combining protein, creatine and HMB. The product expands Abbott’s consumer-health offering and targets growing demand for mainstream muscle and wellness products. Abbott Introduces Ensure Max Protein 3-in-1 Muscle Support
• Positive Sentiment: Abbott also announced an exclusive U.S. partnership connecting its Lingo glucose-monitoring wearable with Berry Street’s live nutrition coaching, potentially increasing adoption of its consumer diabetes and metabolic-health products. Abbott Ties Glucose Tracking to Live Nutrition Coaching
• Neutral Sentiment: Wall Street’s average brokerage recommendation is equivalent to Buy, while Zacks reported elevated investor attention. However, the articles caution that analyst recommendations can be overly optimistic and are not, by themselves, a strong valuation signal. Is It Worth Investing in Abbott Based on Wall Street’s Bullish Views?
• Negative Sentiment: Commentary notes that Abbott is not showing rapid growth and trades at a relatively demanding earnings multiple. Its long record of quarterly dividend payments—411 consecutive quarters—supports the income case, but slower growth may limit near-term upside. Is Abbott Laboratories a Dividend Bargain After Its 2026 Selloff?

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ABT shares. Robert W. Baird began coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price objective on the stock. Bank of America dropped their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. JPMorgan Chase & Co. raised their price target on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $130.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 17th. Finally, TD Cowen reissued a “buy” rating and set a $135.00 target price on shares of Abbott Laboratories in a research report on Tuesday, September 8th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $118.88.

Abbott Laboratories Stock Performance

Shares of ABT opened at $98.46 on Friday. The company has a market capitalization of $170.37 billion, a PE ratio of 31.86, a price-to-earnings-growth ratio of 1.83 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. Abbott Laboratories has a one year low of $81.97 and a one year high of $135.13. The company’s fifty day moving average price is $106.37 and its 200 day moving average price is $98.34.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.6%. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

About Abbott Laboratories

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.